00:43 , Jan 13, 2018 |  BioCentury  |  Finance

Choosy investors

  Despite losing steam in 4Q17, the broad-based recovery in biotech stocks last year has left investors generally comfortable with current valuations, and hence less optimistic that the sector indexes will outpace the broader market...
00:29 , May 2, 2017 |  BC Week In Review  |  Financial News

BioPharmX completes $5M registered direct offering

Dermatology company BioPharmX Corp. (NYSE-M:BPMX) raised $5 million through the sale of 6.4 million shares at $0.78 in a registered direct offering on April 28. Roth Capital Partners was the placement agent. Investors also received...
22:15 , Jan 6, 2017 |  BioCentury  |  Finance

Good riddance

  Investors aren’t lamenting the end of 2016, but they are pinned between anxiety and optimism for the year ahead. The anxiety stems from uncertainty about U.S. government policies for healthcare under the new administration....
21:58 , Jan 5, 2017 |  BC Week In Review  |  Clinical News

BPX-01: Completed Ph II enrollment

BioPharmX completed enrollment of 225 patients with moderate to severe inflammatory, non-nodular acne vulgaris in the double-blind, placebo-controlled, U.S. Phase IIb OPAL trial evaluating about 1 g of 1% or 2% BPX-01 topical gel once...
00:10 , Dec 1, 2016 |  BC Week In Review  |  Financial News

BioPharmX completes follow-on

BioPharmX raised $12.5 million through the sale of 31.5 million class A units at $0.35 and 1,515 class B units at $1,000 in a follow-on underwritten by Roth Capital Partners. Each class A unit comprises...
07:00 , Oct 24, 2016 |  BC Week In Review  |  Financial News

BioPharmX proposes follow-on

BioPharmX Corp. (NYSE-M:BPMX), Menlo Park, Calif.  Business: Drug delivery, Dermatology, Neurology  Date announced: 2016-10-14  Type: Follow-on  To be raised: Up to $8 million  Shares: TBD  Price prior: $0.34  Underwriter: Roth Capital Partners  Note: Investors will...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Financial News

BioPharmX completes direct public offering

BioPharmX Corp. (NYSE-M:BPMX), Menlo Park, Calif.   Business: Drug delivery, Dermatology, Neurology   Date completed: 2016-09-26   Type: Direct public offering   Raised: $930,000   Shares: 1.6 million   Price: $0.60   Shares after offering:...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Financial News

BioPharmX completes direct public offering

BioPharmX Corp. (NYSE-M:BPMX), Menlo Park, Calif.   Business: Drug delivery, Dermatology, Neurology   Date completed: 2016-09-26   Type: Direct public offering   Raised: $930,000   Shares: 1.6 million   Price: $0.60   Shares after offering:...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

BPX-01: Phase IIa final data

Final data from 24 acne patients in the per protocol (PP) population of a double-blind, U.S. Phase IIa trial showed that once-daily 1% topical BPX-01 significantly reduced mean P. acnes bacteria from baseline to week...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

BPX-01: Phase IIb started

BioPharmX began the double-blind, placebo-controlled, U.S. Phase IIb OPAL trial to evaluate about 1 g of 1% or 2% BPX-01 topical gel once daily for 12 weeks in about 225 patients with moderate to severe...